Cargando…
The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours
RATIONALE: The novel opioid receptor antagonist, GSK1421498, has been shown to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating, in animals and humans. Here, we report new data on the receptor pharmacology of GSK121498, in comparison to naltrexone, naloxo...
Autores principales: | Kelly, Eamonn, Mundell, Stuart J., Sava, Anna, Roth, Adelheid L., Felici, Antonio, Maltby, Kay, Nathan, Pradeep J., Bullmore, Edward T., Henderson, Graeme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281354/ https://www.ncbi.nlm.nih.gov/pubmed/24973897 http://dx.doi.org/10.1007/s00213-014-3666-3 |
Ejemplares similares
-
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice
por: Ripley, Tamzin L., et al.
Publicado: (2015) -
The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013) -
Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype
por: Ziauddeen, Hisham, et al.
Publicado: (2016) -
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects
por: Ziauddeen, H, et al.
Publicado: (2013) -
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects
por: Ziauddeen, H, et al.
Publicado: (2014)